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Abstract
Background: Dihydropteridine reductase (DHPR) is one of the key enzymes for 
maintaining in the organism the supply of tetrahydrobiopterin (BH4), an essential 
cofactor for aromatic amino acid hydroxylases. Its dysfunction causes the condition 
of hyperphenylalaninemia together with the lack of neurotransmitters.
Methods: We report a patient with biochemically diagnosed DHPR deficiency, with 
extensive molecular investigations undertaken to detect variations in quinoid dihy-
dropteridine reductase (QDPR) gene. Sanger sequencing of QDPR coding regions, 
exome sequencing, QDPR mRNA PCR, and karyotyping were followed by trio ge-
nome sequencing.
Results: Short-read genome sequencing revealed a homozygous 9-Mb inversion 
disrupting QDPR. Structural variant breakpoints in chromosome 4 were located to 
intron 2 of QDPR at Chr4(GRCh38):g.17505522 and in intron 8 of the ACOX3 gene, 
Chr4(GRCh38):g.8398067). Both nonrelated parents carried the variant in heterozy-
gous state. The inversion was not present in gnomAD structural variant database.
Conclusion: Identification of the exact breakpoints now allows further straightfor-
ward molecular genetic testing of potential carriers of the inversion. This study ex-
tends the pathogenic variant spectrum of DHPR deficiency and highlights the role of 
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1 |  INTRODUCTION
Tetrahydrobiopterin (BH4) is an important cofactor for aro-
matic amino acid hydroxylases (phenylalanine (Phe), tyrosine 
(Tyr), and tryptophan hydroxylase) as well as nitric oxide 
synthase (Opladen, Hoffmann, & Blau, 2012). Disturbances 
in BH4 synthesis or regeneration can lead to disrupted ho-
meostasis of Phe and neurotransmitter synthesis, thus caus-
ing hyperphenylalaninemia (HPA); additionally, the lack of 
neurotransmitters dopamine, noradrenaline, and serotonin 
may lead to severe cognitive and motor delay (Opladen et 
al., 2012; Werner, Blau, & Thony, 2011). One of the key en-
zymes for maintaining BH4 supply in the organism is dihy-
dropteridine reductase (DHPR, EC 1.6.99.7) responsible for 
BH4 regeneration, which is encoded by the quinoid dihydrop-
teridine reductase (QDPR) gene (OMIM #612676). Biallelic 
pathogenic variants in QDPR gene lead to BH4-deficient 
HPA, accompanied with a severe biogenic amines deficiency 
(OMIM #261630). DHPR deficiency is the second most com-
mon form of BH4 deficiency (Blau, 2016). According to the 
online register of BH4 deficiencies (http://www.biopku.org/
biode f/BIODEF) (Opladen et al., 2012), 303 cases of DHPR 
deficiency have been recorded. The QDPR locus-specific 
database PNDdb (http://www.biopku.org/home/pnddb.asp) 
tabulates information of 85 disease-causing QDPR variants, 
50 of them missense, 8 nonsense, 8 small deletions, 7 splice 
variants, 6 small insertions/duplication, 4 indels, 1 large de-
letion, and 1 synonymous variant. One intronic variant re-
sulting in cryptic splice site activation has been reported in a 
patient with DHPR deficiency (Ikeda et al., 1997).
2 |  CASE REPORT
Here we report a case where DHPR deficiency was diag-
nosed in 1992 by analyzing neurotransmitter and pterin me-
tabolites and confirmed by measuring DHPR activity. The 
DNA variant causing this phenotype remained unsolved until 
now, despite repeated targeted sequencing of the QDPR gene 
coding regions and exome sequencing (ES).
The proband was born as the first child of unrelated 
Estonian parents following a normal pregnancy with birth 
weight 3,365 g, length 48 cm, and Apgar scores of 8 and 9 
at 1 and 5 min, respectively. Since the first week of life, the 
proband's mother noticed muscular rigidity and lack of eye 
contact. Later permanent constipation, and contiguous peri-
ods of crying with only brief spontaneous laughter was noted. 
At the age of 6 months she was hospitalized for further inves-
tigations of developmental delay and spasticity. On metabolic 
screening, HPA (plasma Phe = 1,179 µmol/L) was detected, 
and a low-Phe diet was started assuming that this child had 
classical phenylketonuria. However, she did not improve clin-
ically and seizures started one month later. Accordingly, a 
high suspicion of disturbance in BH4 metabolism arose. At 
the age of 8  months, Phe loading test (0.1  g Phe/kg body 
weight) was performed at Vilnius Children's Hospital, 
Lithuania, resulting in a sharp increase in Phe level: at 0 min 
after consumption—Phe 23.4  µmol/L, Tyr 79.9  µmol/L; at 
65 min—Phe 629.3 µmol/L, Tyr 71.4 µmol/L; at 100 min—
Phe 1,083  µmol/L, Tyr 91.4  µmol/L). Furthermore, BH4 
loading test (7 mg BH4/kg body mass) on the background of 
increased Phe level was performed at the age of 9 months, 
resulting in variable changes in plasma Phe and Tyr: 0 hr—
Phe 1,400 µmol/L, Tyr 55.8 µmol/L; 4 hr—Phe 923.7 µmol/L 
Tyr 55.8 µmol/L; 8 hr—Phe 1555.3 µmol/L Tyr 62.8 µmol/L; 
24 hr—Phe 892.3 µmol/L Tyr 48.8 µmol/L, indicating possi-
ble disturbance in BH4 synthesis/regeneration.
At the age of 11 months, the child was reinvestigated for 
BH4 cofactor disorders. BH4 loading test, urinary biopterin 
analysis, and cerebrospinal (CSF) neurotransmitter anal-
yses showed biochemical abnormalities indicating DHPR 
deficiency. Neopterin in urine was normal: 1.6  mmol/mol 
creat (normal: 1.1–4.0  mmol/mol creat) and biopterin was 
significantly increased: 12.3 mmol/mol creat (normal: 0.5–
3.0  mmol/mol creat), resulting in elevated percentage of 
biopterin (88%). BH4 loading test (20 mg/kg body weight) 
resulted in blood Phe reduction from initial 496 µmol/L to 
254 µmol/L and, Phe 169 µmol/L, 4 and 8 hr after BH4 ad-
ministration, respectively. Investigation of CSF neurotrans-
mitters showed normal neopterin—18  nmol/L (normal: 
9–40 nmol/L) and elevated biopterin—65 nmol/L (normal: 
10–50  nmol/L), very low 5-HIAA—19  nmol/L (normal: 
114–336  nmol/L) and HVA—170  nmol/L (normal: 295–
932 nmol/L), 5-MTHF—26 nmol/L (normal: 64–182 nmo-
l/L), all compatible with DHPR deficiency. Details of all 
biochemical analyses are given in Table 1. The diagnosis was 
confirmed by the absent DHPR activity in dried blood (<0.5 
µU/g Hb; normal: 2.3–3.8). Accordingly, substitution therapy 
structural variants in recessive metabolic disorders. To our knowledge, this is the first 
report on a large, canonical (rather than complex) homozygous pathogenic inversion 
detected by genome sequencing.
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with L-DOPA/carbidopa, 5-OH-tryptophan and folinic acid 
as well as continuation of the low-Phe diet and anticonvulsive 
therapy were introduced.
At the age of 18 months, after 8 months on neurotrans-
mitter substitution therapy, CSF analysis of pterins and 
neurotransmitter metabolites was unremarkable. The child 
exhibited her highest psychomotor abilities at the age of 
30 months, having eye contact, being able to independently 
grasp toys and insert them into her mouth; to take a kneeling 
position and perform jerky motions, and laugh at a whirligig. 
Since the age of 3 years, her skills started to deteriorate in 
parallel with slowly progressing muscular atrophy. The child 
died at the age of 8 years despite treatment. At the time of her 
death, she exhibited profound developmental delay, general-
ized seizures and almost no acquired skills.
In two of the following pregnancies, prenatal testing 
was performed using an enzyme assay—DHPR activity 
measurement (in chorionic biopsy/amniotic fluid and um-
bilical cord blood)—which showed mildly decreased level 
of DHPR activity consistent with fetal heterozygosity for a 
QDPR variant. In an effort to identify the causative vari-
ants for DHPR deficiency, QDPR exons were Sanger se-
quenced four times by different laboratories in the index 
patient and her parents, but no potentially pathogenic vari-
ants were identified.
3 |  METHODS
3.1 | Ethics
All activities performed during this study were approved by 
Research Ethics Committee of the University of Tartu (ap-
proval date 21.09.2015 number 251/T-6) and were strictly in 
accordance with the Declaration of Helsinki. Informed con-
sent for carrying out research was obtained from the family 
of the proband.
3.2 | Exome sequencing
Exome sequencing of the index patient was carried out in the 
Estonian Genome Centre at the University of Tartu. DNA 
library was prepared using Nextera Rapid Capture Exome 
37  Mb kit (Illumina Inc.) according to the manufacturer's 
protocols. The HiSeq 2,500 (Illumina Inc.) platform was 
used for paired-end 2 × 100 bp sequencing. The bioinformat-
ics data processing made use of BWA (Li & Durbin, 2009), 
which mapped the reads to the hg19 reference genome, 
and different Picard (v2.2.2) and Genome Analysis Toolkit 
(GATK) (v3.5-0) tools to mark duplicate reads, recalibrate 
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An in-house variant annotation pipeline was used. 
Annotations included, but were not limited to reference da-
tabases from ExAC (Lek et al., 2016) and 1,000 Genomes 
Project (Genomes Project et al., 2015), and ClinVar patho-
genicity annotations (Landrum et al., 2016), as well as HPO 
terms (Kohler et al., 2014) and OMIM disorders as gene-
based annotations. Additionally, allele counts from our in-
house database of variants detected among all NGS analyses 
(panels and ES) performed in our department (654 samples) 
were annotated to every detected variant.
CNVs were called using CoNIFER software (Krumm 
et al., 2012). First, reads per thousand bases per million reads 
sequenced (RPKM) values were calculated for each sample 
separately. Second, all available samples using the same li-
brary preparation kit were joined for CNV calling. CNV de-
tection and plot generation for detected CNVs were carried 
out subsequently according to CoNIFER guidelines.
3.3 | mRNA study
Blood for mRNA analysis was collected from the parents 
and a control, to obtain cDNA from QDPR and analyze 
the integrity of the cDNA by PCR. PCR was performed 
from the cDNA synthesized from blood extracted RNA 
(Tempus™ Spin RNA Isolation Kit, incl DNAse treat-
ment) with SuperScriptTM III Reverse Transcriptase 
(Invitrogen) according to the manufacturer's protocol; 
the first strand cDNA was synthesized using Random 
Hexamers (Applied Biosystem). The primers (QDPR_Rev 
GTGACTTTTCTGGCAGGCCCCTCATA and QDPR_
For GGAGCTGCGGGAGCCGGGCT) were designed 
from UTR regions of the transcript (NCBI Reference 
Sequence: NM_000320.3), thus an alternative (93 bp) exon 
was included into the PCR products with predicted 809 and 
716  bp fragments depending on the presence/absence of 
alternative exon. Phusion Hot Start II DNA Polymerase 
(ThermoFisher) was used for the PCR reaction.
3.4 | Genome sequencing
Genome sequencing (GS) and data processing were performed 
by the Genomics Platform at the Broad Institute of MIT and 
Harvard. PCR-free preparation of sample DNA (350 ng input 
at >2 ng/µl) is accomplished using Illumina HiSeq X Ten v2 
chemistry. Libraries are sequenced to a mean target coverage 
of >30×. GS data were processed through a pipeline based on 
Picard, using base quality score recalibration and local realign-
ment at known indels. The BWA aligner was used for mapping 
reads to the human genome build 38. Single-nucleotide vari-
ants (SNVs) and insertions/deletions (indels) are jointly called 
across all samples using Genome Analysis Toolkit (GATK) 
HaplotypeCaller package version 3.4. Default filters were ap-
plied to SNV and indel calls using the GATK Variant Quality 
Score Recalibration (VQSR) approach. Annotation was per-
formed using Variant Effect Predictor (VEP). Lastly, the vari-
ant call set was uploaded to seqr for collaborative analysis 
between the Center Mendelian Genomics and investigator.
3.5 | Chromosome analysis
Karyotype analysis from peripheral blood lymphocytes 
was performed by using conventional GTG-banding tech-
nique (G-bands by trypsin using Giemsa; band level 550). 
Karyotypes were described according to the International 
System for Human Cytogenetic Nomenclature (ISCN2016), 
(Gonzalez Garcia & Meza-Espinoza, ). Both karyotypes were 
performed at the 550-band level.
4 |  RESULTS
4.1 | Exome sequencing
Singleton ES failed to reveal pathogenic variants in QDPR 
gene or in other genes involved in pterin metabolism. 
However, ES analysis indicated homozygosity around 
the QDPR gene locus, as only homozygous variants 
were detected in 10-Mb region chr4:7433652-17817262 
(GRCh38).
4.2 | Genome sequencing
Following the initial investigations, predominantly after ob-
taining the results from ES, the main hypothesis was that 
the patient may have a homozygous noncoding rearrange-
ment which disrupts QDPR expression. To explore this hy-
pothesis, trio GS was performed. Although there were no 
rare coding variants, concordant with previous studies, two 
rare homozygous intronic variants in the 3’ region of QDPR 
were detected (c.*119+4759T>C and c.*119+12119G>A, 
ENST00000513615.5). Both variants were heterozygous in 
both parents. In the gnomAD database, both variants have an 
allele frequency below 0.1% with no homozygotes (Karczewski 
et al., 2019). However, as the functional consequence is hard 
to predict for intronic single-nucleotide variants (SNVs), we 
searched further for other classes of variants. By visual in-
specting aligned sequencing reads, a possible structural vari-
ant (SV) breakpoint at Chr4(GRCh38):g.17505522 (Figure 1c) 
was detected, which locates to intron 2 of QDPR. The other 
breakpoint was discovered by paired read mapping and split 
read analysis, revealing it localized to intron 8 of the ACOX3 
gene (Chr4(GRCh38):g.8398067) (Figure 1c). Thus, a possible 
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9 megabase (Mb) inversion of 4p was suspected (Figure 1a,b). 
We also performed post hoc analysis using three structural 
variant callers on GS data: Manta (Chen et al., 2016), DELLY 
(Rausch et al., 2012), and Smoove (Layer, Chiang, Quinlan, 
& Hall, 2014). All three SV callers detected the inversion and 
genotyped it as homozygous in the proband and heterozygous 
in both parents. To validate the inversion we designed oli-
gonucleotide primers (Figure 1b, Table 2) to perform PCR 
amplification, and subsequent Sanger validation around the 
breakpoints. As expected, the proband did not have any PCR 
product using F1-R1, and F2-R2 primer pairs, whereas F1-F2 
and R1-R2 primer pairs gave PCR product with predicted se-
quence over both breakpoints (Figure 1d). This 9-Mb inversion 
was not observed in 10,782 unrelated genomes with SV calls 
in gnomAD (Collins et al., 2019); in fact, no inversions within 
544kb of QDPR were observed in gnomAD, further support-
ing the rareness and probable pathogenicity of this inversion. 
Importantly, gnomAD database has 2,297 Estonians in its GS 
dataset, thus we can conclude that this inversion is very rare 
among Estonians as well. As gnomAD SV calling pipeline in-
corporated two of the tools used in this study for SV calling 
(Manta and DELLY), then it is highly unlikely that the variants 
F I G U R E  1  Identification of a new homozygous structural variant in a biochemically diagnosed patient with dihydropteridine reductase 
(DHPR) deficiency: a 9 Mb inversion between 4p16.1 and 4p15.32. (a) Chromosome 4 ideogram. The described 9-Mb inversion is marked by 
the red box. (b) Scheme of the inversion in the context of ACOX3 and QDPR genes. F1, R1, F2, R2 schematically represent the PCR primer 
design relative to the reference (WT) genome. (c) The aligned sequencing reads around detected breakpoints BP1 and BP2 visualized using The 
Integrative Genomics Viewer (IGV). Soft-clipped nucleotides are highlighted and nucleotides shown. (d) Validation studies confirming the variant 
by PCR using primers F1-R1 and F1-F2. C—child, M—mother, F—Father, WT—wild-type control
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are absent from gnomAD database just due to the differences 
in SV calling algorithms. Homozygosity mapping from GS 
data was performed using PLINK 1.9 (Chang et al., 2015), and 
the homozygous stretch encompassing the inversion was con-
firmed for the region chr4:7452118-18823503 (GRCh38), and 
no other homozygous stretches larger than 5 megabases were 
detected, thus excluding the parental consanguinity. The de-
tected inversion was submitted to ClinVar database (accession 
number SCV000898485) and to the locus-specific PNDdb. 
Data available on request from the authors.
4.3 | Chromosome analysis
After finding the large inversion, we investigated whether 
the inversion could be detected with a regular chromosomal 
microscopy analysis (karyotyping with G bands) in both het-
erozygous parents. Our result showed that the inversion of 
4p16.1-p15.32 is not detectable by GTG-banding techniques, 
as inversion points 4p16.1 and 4p15.32 form symmetrical 
pattern around the band 4p16.2 (Figure 2). Accordingly, in 
spite of the ca 10 MB size of the inversion, the inversion is 
not detectable by G-banding.
4.4 | mRNA analysis
For the identification of variants in QDPR, we performed 
an mRNA studies to analyze the integrity of the cDNA by 
PCR in heterozygous parental samples (no RNA samples 
were stored from the proband). This analysis did not reveal 
any different patterns between the parents of the proband 
and the control, thus indicating the lack of possible mRNA 
products with abnormal length (Figure 3). Despite the 
qualitative essence of the performed reactions, a hint for 
decreased quantity of obtained QDPR cDNA could be re-
trieved from the visually observed lower intensity of the 
PCR products of the parents compared to the ones from 
the control.
5 |  DISCUSSION
This case illustrates both the advantages of GS and the 
clinical importance of SVs in disease-associated genes 
including the ones where SVs have not been previously 
implicated as a disease mechanism such as QDPR. In this 
family, GS was able to resolve a 27-year-long diagnostic 
odyssey, and now provides the possibility to adequately 
counsel and test family members at risk for being carriers 
for this disorder. As the parents are nonconsanguineous, 
but carry the same inversion and haplotype, this variant 
may not be unique to this family, furthering the importance 
of this novel discovery.
SVs, including inversions, are well recognized as a disease 
mechanism (Collins et al., 2017), but balanced SVs in partic-
ular remain difficult to detect using common molecular DNA 
variant detection assays that typically only focus on coding re-
gions of the genome. Heterozygous and hemizygous inversions 
are known to cause many different disorders. For example, the 
most common variant causing severe hemophilia A is a hemi-
zygous inversion in intron 22 of the F8 gene (Lakich, Kazazian, 
Antonarakis, & Gitschier, 1993). In addition to small intragenic 
inversions, some very large inversion detectable by karyotyping 
has been reported (since the discovery of banding techniques 
for karyotyping). For example, an early study described a phe-
notype-causing homozygous paracentric inversion of chromo-
some 12 inherited from consanguineous parents (Price, Roberts, 
& Laurence, 1987). However, karyotyping does not allow for 
the identification of exact breakpoints and thus the discovery 
of disrupted genes. This limitation may be overcome by labo-
rious breakpoint searching using PCR and Sanger sequencing, 
F I G U R E  2  Karyotype analysis from peripheral blood 
lymphocytes of the parents of the DHPR deficient proband with 9 Mb 
inversion does not reveal observable pattern abnormality
F I G U R E  3  PCR analysis of QDPR from the cDNA obtained 
from peripheral blood mRNA of the parents of the proband and 
control. No products of abnormal length can be observed, predicted 
809 and 716 bp fragments are present. neg: includes all ingredients and 
primers without cDNA; marker: SolisBiodyne 100 bp DNA ladder
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as seen in a recently published homozygous inversion causing 
Phosphoglucomutase 1 deficiency (Yokoi et al., 2019). A sys-
tematic approach was taken by Redin et al. in a large study aim-
ing to map breakpoints of balanced chromosomal aberrations 
in individuals with congenital anomalies (Redin et al., 2017) 
using a lower-resolution “long-insert” (also known as “mate-
pair”) GS technology. The authors demonstrated that in third 
of the patients carrying cytogenetically balanced aberration, 
breakpoint mapping revealed disruption of a gene probably 
contributing to the phenotype. While GS has facilitated detec-
tions of some disease causing inversions also in the absence of 
prior suspicion to chromosomal rearrangement (Grigelioniene 
et al., 2017; Kim et al., 2015), these variants remain rare and 
probably under detected as GS is still much less available than 
ES in both research and clinical settings. Moreover, even if 
using GS, the short-read sequencing technologies like Illumina 
sequencing used in this study, may have reduced sensitivity in 
SV detection due to repetitive sequences around breakpoints or 
more complex nature of some SVs. Thus, long-read sequencing 
approaches like single molecule real-time (SMRT) sequenc-
ing by Pacific Biosciences or nanopore sequencing by Oxford 
Nanopore Technologies Inc. may be needed to identify some 
SVs. To our knowledge, this is the first report on a large, canon-
ical (rather than complex) homozygous pathogenic inversion 
detected by GS. In addition to simple inversions, GS can be 
used to resolve more complex SVs, where inversions may be 
accompanied by deletions or duplications (Sanchis-Juan et al., 
2018). Accurate detection of SVs also requires adequate vari-
ant calling software. Our post hoc analysis of three SV_calling 
tools demonstrated that all three tools identified the inversion 
correctly, illustrating that many currently available algorithms 
are capable of detecting disease causing inversions.
Interestingly, the second breakpoint of our patient's inver-
sion was mapped into the intronic area between exons 8 and 9 
of the ACOX3 gene encoding pristanoyl-CoA oxidase (OMIM 
*603402). This enzyme has been shown to be involved in the 
degradation of the branched-chain fatty acids (Ferdinandusse et 
al., 2018; Vanhooren, Marynen, Mannaerts, & Van Veldhoven, 
1997), but its deficiency is probably compensated for by other 
peroxisomal acyl-CoA oxidases and we do not feel that this 
gene disruption is clinically manifesting in our patient.
From a clinical perspective, the current report presents an 
additional strategy for finding a molecular diagnoses, if bio-
chemical features are suggestive of a disorder and conventional 
or even the most up-to-date methods fail to identify the caus-
ative variant. Although high-throughput targeted sequencing 
has been shown to be very effective in solving BH4-deficient 
HPAs (Trujillano et al., 2014), our case reiterates the additional 
benefits associated with GS. This inversion maintained all of 
the exons of QDPR intact, as the breakpoint occurred deep 
inside of an intron, thus presented completely normal results 
from PCR and Sanger sequencing as well as ES. Obviously, 
the presence of a breakpoint inside a gene eliminates the 
possibility of synthesizing normal functional mRNA and re-
spective protein. We also demonstrate the inability of standard 
cytogenetic methods to reveal this inversion. After mapping 
the breakpoints in the genome of the index patient, further di-
agnostic testing in the family can easily be performed by sim-
ple PCR reactions like presented in Figure 1d, and/or Sanger 
sequencing, enabling significantly faster analysis and consul-
tation, especially for prenatal diagnosis.
ACKNOWLEDGMENTS
The authors express their gratitude toward Anne Romstad 
and Riin Tamm, who helped with Sanger sequencing of 
QDPR exons, Piret Ilisson for excellent karyotyping, Dr 
Michael Kandler in Erlangen University Children's Hospital, 
Germany and Dr Vaclovas Jurgelevičius in University of 
Vilnius Medical Genetics Centre, Lithuania, for initial stud-
ies of biopterin metabolism.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ORCID
Sander Pajusalu   https://orcid.org/0000-0002-5435-0781 
Katrin Õunap   https://orcid.org/0000-0002-4594-6364 
REFERENCES
Blau, N. (2016). Genetics of phenylketonuria: Then and now. Human 
Mutation, 37(6), 508–515. https ://doi.org/10.1002/humu.22980 
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., 
& Lee, J. J. (2015). Second-generation PLINK: Rising to the chal-
lenge of larger and richer datasets. Gigascience, 4, 7. https ://doi.
org/10.1186/s13742-015-0047-8
Chen, X., Schulz-Trieglaff, O., Shaw, R., Barnes, B., Schlesinger, F., 
Källberg, M., … Saunders, C. T. (2016). Manta: Rapid detection 
of structural variants and indels for germline and cancer sequenc-
ing applications. Bioinformatics, 32(8), 1220–1222. https ://doi.
org/10.1093/bioin forma tics/btv710
Collins, R. L., Brand, H., Karczewski, K. J., Zhao, X., Alföldi, J., Khera, 
A. V., Talkowski, M. E. (2019). An open resource of structural 
variation for medical and population genetics. bioRxiv. https ://doi.
org/10.1101/578674
Collins, R. L., Brand, H., Redin, C. E., Hanscom, C., Antolik, C., Stone, 
M. R., … Talkowski, M. E. (2017). Defining the diverse spectrum 
of inversions, complex structural variation, and chromothripsis in 
the morbid human genome. Genome Biology, 18(1), 36. https ://doi.
org/10.1186/s13059-017-1158-6
Ferdinandusse, S., Denis, S., van Roermund, C. W. T., Preece, M. A., 
Koster, J., Ebberink, M. S., … Wanders, R. J. A. (2018). A novel 
case of ACOX2 deficiency leads to recognition of a third human 
peroxisomal acyl-CoA oxidase. Biochimica et Biophysica Acta 
(BBA) - Molecular Basis of Disease, 1864(3), 952–958. https ://doi.
org/10.1016/j.bbadis.2017.12.032
Genomes Project, Auton, A., Brooks, L. D., Durbin, R. M., Garrison, 
E. P., Kang, H. M., … Abecasis, G. R. (2015). A global reference 
for human genetic variation. Nature, 526(7571), 68–74. https ://doi.
org/10.1038/natur e15393
8 of 8 |   LILLEVÄLI ET AL.
Gonzalez Garcia, J. R., & Meza-Espinoza, J. P. Use of the International 
System for Human Cytogenetic Nomenclature (ISCN). Blood, 
108(12), 3952–3953. https ://doi.org/10.1182/blood-2006-06-031351
Grigelioniene, G., Nevalainen, P. I., Reyes, M., Thiele, S., Tafaj, O., 
Molinaro, A., … Juppner, H. (2017). A large inversion involving GNAS 
exon A/B and all exons encoding gsalpha is associated with autosomal 
dominant pseudohypoparathyroidism type Ib (PHP1B). Journal of 
Bone and Mineral Research, 32(4), 776–783. https ://doi.org/10.1002/
jbmr.3083
Ikeda, H., Matsubara, Y., Mikami, H., Kure, S., Owada, M., Gough, 
T., … Narisawa, K. (1997). Molecular analysis of dihydropteri-
dine reductase deficiency: Identification of two novel mutations in 
Japanese patients. Human Genetics, 100(5–6), 637–642. https ://doi.
org/10.1007/s0043 90050566
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, 
J., Wang, Q., MacArthur, D. G. (2019). Variation across 141,456 
human exomes and genomes reveals the spectrum of loss-of-func-
tion intolerance across human protein-coding genes. bioRxiv. https 
://doi.org/10.1101/531210
Kim, J., Won, H. H., Kim, Y., Choi, J. R., Yu, N., & Lee, K. A. (2015). 
Breakpoint mapping by whole genome sequencing identifies PTH2R 
gene disruption in a patient with midline craniosynostosis and a de novo 
balanced chromosomal rearrangement. Journal of Medical Genetics, 
52(10), 706–709. https ://doi.org/10.1136/jmedg enet-2015-103001
Köhler, S., Doelken, S. C., Mungall, C. J., Bauer, S., Firth, H. V., 
Bailleul-Forestier, I., … Robinson, P. N. (2014). The Human 
Phenotype Ontology project: Linking molecular biology and dis-
ease through phenotype data. Nucleic Acids Research, 42(D1), 
D966–D974. https ://doi.org/10.1093/nar/gkt1026
Krumm, N., Sudmant, P. H., Ko, A., O'Roak, B. J., Malig, M., Coe, B. 
P., … Eichler, E. E. (2012). Copy number variation detection and 
genotyping from exome sequence data. Genome Research, 22(8), 
1525–1532. https ://doi.org/10.1101/gr.138115.112
Lakich, D., Kazazian, H. H. Jr, Antonarakis, S. E., & Gitschier, J. (1993). 
Inversions disrupting the factor VIII gene are a common cause of 
severe haemophilia A. Nature Genetics, 5(3), 236–241. https ://doi.
org/10.1038/ng1193-236
Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, 
S., … Maglott, D. R. (2016). ClinVar: Public archive of interpreta-
tions of clinically relevant variants. Nucleic Acids Research, 44(D1), 
D862–868. https ://doi.org/10.1093/nar/gkv1222
Layer, R. M., Chiang, C., Quinlan, A. R., & Hall, I. M. (2014). LUMPY: 
A probabilistic framework for structural variant discovery. Genome 
Biology, 15(6), R84. https ://doi.org/10.1186/gb-2014-15-6-r84
Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., 
Fennell, T., … MacArthur, D. G. (2016). Analysis of protein-coding 
genetic variation in 60,706 humans. Nature, 536(7616), 285–291. 
https ://doi.org/10.1038/natur e19057
Li, H., & Durbin, R. (2009). Fast and accurate short read alignment with 
Burrows-Wheeler transform. Bioinformatics, 25(14), 1754–1760. 
https ://doi.org/10.1093/bioin forma tics/btp324
Opladen, T., Hoffmann, G. F., & Blau, N. (2012). An international 
survey of patients with tetrahydrobiopterin deficiencies pre-
senting with hyperphenylalaninaemia. Journal of Inherited 
Metabolic Disease, 35(6), 963–973. https ://doi.org/10.1007/
s10545-012-9506-x
Price, H. A., Roberts, S. H., & Laurence, K. M. (1987). Homozygous 
paracentric inversion 12 in a mentally retarded boy: A case report 
and review of the literature. Human Genetics, 75(2), 101–108. https 
://doi.org/10.1007/BF005 91068 
Rausch, T., Zichner, T., Schlattl, A., Stutz, A. M., Benes, V., & 
Korbel, J. O. (2012). DELLY: Structural variant discovery by in-
tegrated paired-end and split-read analysis. Bioinformatics, 28(18), 
i333–i339. https ://doi.org/10.1093/bioin forma tics/bts378
Redin, C., Brand, H., Collins, R. L., Kammin, T., Mitchell, E., Hodge, 
J. C., … Talkowski, M. E. (2017). The genomic landscape of 
balanced cytogenetic abnormalities associated with human con-
genital anomalies. Nature Genetics, 49(1), 36–45. https ://doi.
org/10.1038/ng.3720
Sanchis-Juan, A., Stephens, J., French, C. E., Gleadall, N., Mégy, K., 
Penkett, C., … Carss, K. J. (2018). Complex structural variants in 
Mendelian disorders: Identification and breakpoint resolution using 
short- and long-read genome sequencing. Genome Medicine, 10(1), 
95. https ://doi.org/10.1186/s13073-018-0606-6
Trujillano, D., Perez, B., González, J., Tornador, C., Navarrete, R., 
Escaramis, G., … Estivill, X. (2014). Accurate molecular diagno-
sis of phenylketonuria and tetrahydrobiopterin-deficient hyper-
phenylalaninemias using high-throughput targeted sequencing. 
European Journal of Human Genetics, 22(4), 528–534. https ://doi.
org/10.1038/ejhg.2013.175
Vanhooren, J. C., Marynen, P., Mannaerts, G. P., & Van Veldhoven, P. P. 
(1997). Evidence for the existence of a pristanoyl-CoA oxidase gene 
in man. The Biochemical Journal, 325(Pt 3), 593–599. https ://doi.
org/10.1042/bj325 0593
Werner, E. R., Blau, N., & Thony, B. (2011). Tetrahydrobiopterin: 
Biochemistry and pathophysiology. The Biochemical Journal, 
438(3), 397–414. https ://doi.org/10.1042/BJ201 10293 
Yokoi, K., Nakajima, Y., Ohye, T., Inagaki, H., Wada, Y., Fukuda, 
T., … Kurahashi, H. (2019). Disruption of the responsible gene 
in a phosphoglucomutase 1 deficiency patient by homozygous 
chromosomal inversion. JIMD Reports, 43, 85–90. https ://doi.
org/10.1007/8904_2018_108
How to cite this article: Lilleväli H, Pajusalu S, Wojcik 
MH, et al. Genome sequencing identifies a homozygous 
inversion disrupting QDPR as a cause for 
dihydropteridine reductase deficiency. Mol Genet 
Genomic Med. 2020;8:e1154. https ://doi.org/10.1002/
mgg3.1154
